Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Abnormalities, Drug-Induced | 24 | 2024 | 338 | 7.640 |
Why?
|
Pregnancy Complications | 40 | 2024 | 2942 | 5.380 |
Why?
|
Antipsychotic Agents | 24 | 2023 | 3061 | 3.580 |
Why?
|
Analgesics, Opioid | 31 | 2024 | 3763 | 2.710 |
Why?
|
Antiemetics | 6 | 2023 | 187 | 2.650 |
Why?
|
Pregnancy | 124 | 2024 | 29749 | 2.650 |
Why?
|
Pregnancy Trimester, First | 23 | 2024 | 908 | 2.630 |
Why?
|
Medicaid | 38 | 2024 | 2815 | 2.550 |
Why?
|
Antidepressive Agents | 17 | 2024 | 2890 | 2.290 |
Why?
|
Ondansetron | 5 | 2023 | 95 | 2.170 |
Why?
|
Prenatal Exposure Delayed Effects | 11 | 2024 | 2496 | 2.110 |
Why?
|
Neonatal Abstinence Syndrome | 6 | 2024 | 108 | 1.890 |
Why?
|
Sinusitis | 4 | 2024 | 990 | 1.830 |
Why?
|
Opioid-Related Disorders | 16 | 2024 | 2138 | 1.820 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 2 | 2024 | 33 | 1.800 |
Why?
|
Propensity Score | 26 | 2021 | 1928 | 1.670 |
Why?
|
Drug Prescriptions | 17 | 2021 | 1673 | 1.660 |
Why?
|
Amoxicillin | 2 | 2024 | 180 | 1.650 |
Why?
|
Methylphenidate | 4 | 2024 | 488 | 1.640 |
Why?
|
Antithrombins | 4 | 2020 | 313 | 1.640 |
Why?
|
Valproic Acid | 3 | 2024 | 441 | 1.570 |
Why?
|
Cohort Studies | 81 | 2024 | 41335 | 1.530 |
Why?
|
Heart Defects, Congenital | 15 | 2024 | 4673 | 1.490 |
Why?
|
Nursing Homes | 7 | 2015 | 1082 | 1.470 |
Why?
|
Databases, Factual | 30 | 2024 | 8035 | 1.460 |
Why?
|
Prescription Drugs | 8 | 2024 | 630 | 1.450 |
Why?
|
Pharmacoepidemiology | 8 | 2020 | 350 | 1.410 |
Why?
|
Amphetamine | 4 | 2024 | 224 | 1.400 |
Why?
|
Warfarin | 7 | 2020 | 1518 | 1.390 |
Why?
|
Pre-Eclampsia | 7 | 2024 | 1229 | 1.380 |
Why?
|
Drug Utilization | 11 | 2019 | 1195 | 1.370 |
Why?
|
Placenta Diseases | 2 | 2022 | 196 | 1.350 |
Why?
|
Buprenorphine | 4 | 2024 | 654 | 1.310 |
Why?
|
Pregnancy Complications, Infectious | 7 | 2022 | 2125 | 1.280 |
Why?
|
Pregnancy Outcome | 15 | 2024 | 2907 | 1.220 |
Why?
|
United States | 106 | 2024 | 72461 | 1.190 |
Why?
|
Premature Birth | 9 | 2024 | 1771 | 1.160 |
Why?
|
Congenital Abnormalities | 5 | 2020 | 704 | 1.120 |
Why?
|
Infant, Newborn | 43 | 2024 | 26181 | 1.090 |
Why?
|
Oxytocics | 3 | 2015 | 65 | 1.070 |
Why?
|
Metformin | 6 | 2024 | 912 | 1.070 |
Why?
|
Female | 178 | 2024 | 391270 | 1.060 |
Why?
|
Uterine Inertia | 3 | 2015 | 27 | 1.040 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 5 | 2024 | 3701 | 1.020 |
Why?
|
Anticoagulants | 7 | 2020 | 4897 | 1.010 |
Why?
|
Persistent Fetal Circulation Syndrome | 2 | 2015 | 80 | 0.980 |
Why?
|
Parturition | 3 | 2022 | 446 | 0.910 |
Why?
|
Abruptio Placentae | 3 | 2022 | 118 | 0.900 |
Why?
|
Mood Disorders | 3 | 2020 | 1124 | 0.880 |
Why?
|
Anticonvulsants | 7 | 2024 | 1879 | 0.870 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2021 | 452 | 0.870 |
Why?
|
Clubfoot | 1 | 2024 | 87 | 0.860 |
Why?
|
Humans | 212 | 2024 | 760621 | 0.850 |
Why?
|
Young Adult | 63 | 2024 | 58741 | 0.840 |
Why?
|
Prenatal Care | 4 | 2020 | 1129 | 0.810 |
Why?
|
Adult | 107 | 2024 | 219994 | 0.810 |
Why?
|
Gastroschisis | 1 | 2023 | 99 | 0.790 |
Why?
|
Comparative Effectiveness Research | 4 | 2019 | 718 | 0.790 |
Why?
|
Maternal Exposure | 3 | 2020 | 1045 | 0.790 |
Why?
|
Neural Tube Defects | 1 | 2024 | 254 | 0.780 |
Why?
|
Live Birth | 3 | 2022 | 512 | 0.770 |
Why?
|
Cleft Palate | 4 | 2020 | 587 | 0.750 |
Why?
|
Foramen Ovale, Patent | 1 | 2024 | 214 | 0.750 |
Why?
|
Azabicyclo Compounds | 1 | 2021 | 68 | 0.740 |
Why?
|
Abortion, Spontaneous | 2 | 2023 | 530 | 0.740 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2024 | 491 | 0.740 |
Why?
|
Risk | 17 | 2021 | 9631 | 0.730 |
Why?
|
Insurance Claim Review | 5 | 2020 | 738 | 0.720 |
Why?
|
Candidiasis, Vulvovaginal | 1 | 2020 | 24 | 0.710 |
Why?
|
Psychotropic Drugs | 4 | 2024 | 883 | 0.700 |
Why?
|
Data Mining | 3 | 2021 | 553 | 0.700 |
Why?
|
Hydroxychloroquine | 3 | 2021 | 427 | 0.700 |
Why?
|
Vomiting | 2 | 2020 | 650 | 0.690 |
Why?
|
Anti-Bacterial Agents | 7 | 2024 | 7408 | 0.680 |
Why?
|
Fluconazole | 1 | 2020 | 155 | 0.680 |
Why?
|
Narcotic Antagonists | 1 | 2024 | 583 | 0.670 |
Why?
|
Acetamides | 1 | 2021 | 256 | 0.660 |
Why?
|
Homes for the Aged | 2 | 2012 | 272 | 0.660 |
Why?
|
Tramadol | 3 | 2024 | 60 | 0.660 |
Why?
|
Adolescent | 51 | 2024 | 87810 | 0.650 |
Why?
|
Nausea | 2 | 2020 | 678 | 0.650 |
Why?
|
Quinolones | 1 | 2022 | 377 | 0.650 |
Why?
|
Central Nervous System Stimulants | 3 | 2024 | 1174 | 0.640 |
Why?
|
Infant, Newborn, Diseases | 3 | 2022 | 592 | 0.630 |
Why?
|
Haloperidol | 2 | 2018 | 389 | 0.630 |
Why?
|
Stillbirth | 5 | 2024 | 368 | 0.610 |
Why?
|
Depression | 6 | 2024 | 8044 | 0.600 |
Why?
|
Postpartum Hemorrhage | 6 | 2020 | 265 | 0.600 |
Why?
|
Infant, Small for Gestational Age | 5 | 2024 | 460 | 0.580 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2019 | 1259 | 0.570 |
Why?
|
Diabetes Mellitus, Type 2 | 10 | 2024 | 12293 | 0.570 |
Why?
|
Methadone | 5 | 2024 | 320 | 0.560 |
Why?
|
Depressive Disorder | 3 | 2014 | 3726 | 0.560 |
Why?
|
Cleft Lip | 2 | 2020 | 504 | 0.550 |
Why?
|
Dementia | 5 | 2015 | 2649 | 0.540 |
Why?
|
Insurance, Health | 8 | 2024 | 2501 | 0.520 |
Why?
|
Hypoglycemic Agents | 9 | 2024 | 3150 | 0.520 |
Why?
|
Investments | 1 | 2017 | 148 | 0.510 |
Why?
|
Child | 32 | 2024 | 79806 | 0.500 |
Why?
|
Administration, Oral | 6 | 2020 | 4035 | 0.500 |
Why?
|
Atrial Fibrillation | 6 | 2020 | 5209 | 0.500 |
Why?
|
Antifungal Agents | 1 | 2020 | 749 | 0.490 |
Why?
|
Diabetes, Gestational | 3 | 2021 | 1242 | 0.490 |
Why?
|
Bacterial Infections | 1 | 2023 | 1403 | 0.480 |
Why?
|
Bradycardia | 1 | 2016 | 299 | 0.480 |
Why?
|
Clinical Coding | 1 | 2016 | 181 | 0.470 |
Why?
|
Prevalence | 19 | 2024 | 15687 | 0.470 |
Why?
|
Research Design | 6 | 2019 | 6180 | 0.470 |
Why?
|
Contraception Behavior | 2 | 2020 | 180 | 0.460 |
Why?
|
Stroke | 13 | 2020 | 9962 | 0.460 |
Why?
|
Benzodiazepines | 3 | 2017 | 1131 | 0.460 |
Why?
|
Hospitalization | 12 | 2021 | 10790 | 0.440 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1725 | 0.440 |
Why?
|
Epidemiology | 1 | 2016 | 278 | 0.440 |
Why?
|
Psychotic Disorders | 3 | 2018 | 3193 | 0.440 |
Why?
|
Antirheumatic Agents | 2 | 2021 | 1374 | 0.440 |
Why?
|
Risk Assessment | 14 | 2022 | 24123 | 0.440 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1091 | 0.430 |
Why?
|
Acute Disease | 6 | 2024 | 7269 | 0.430 |
Why?
|
Pregnancy Complications, Cardiovascular | 5 | 2024 | 516 | 0.430 |
Why?
|
Piperazines | 2 | 2021 | 2525 | 0.430 |
Why?
|
Hypnotics and Sedatives | 1 | 2021 | 1178 | 0.430 |
Why?
|
Risk Factors | 31 | 2024 | 74359 | 0.420 |
Why?
|
Terminally Ill | 1 | 2015 | 240 | 0.420 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2024 | 4357 | 0.410 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2017 | 1523 | 0.410 |
Why?
|
Insurance Benefits | 1 | 2014 | 191 | 0.410 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2061 | 0.400 |
Why?
|
Comorbidity | 6 | 2021 | 10551 | 0.390 |
Why?
|
Middle Aged | 58 | 2024 | 220352 | 0.390 |
Why?
|
Bipolar Disorder | 4 | 2024 | 5078 | 0.380 |
Why?
|
Male | 64 | 2024 | 359744 | 0.380 |
Why?
|
Risk Adjustment | 1 | 2015 | 601 | 0.370 |
Why?
|
Drug Therapy, Combination | 5 | 2024 | 6498 | 0.370 |
Why?
|
International Classification of Diseases | 5 | 2024 | 894 | 0.370 |
Why?
|
Cost-Benefit Analysis | 6 | 2017 | 5508 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3334 | 0.370 |
Why?
|
Antiviral Agents | 3 | 2022 | 3061 | 0.370 |
Why?
|
Mortality | 3 | 2013 | 2916 | 0.360 |
Why?
|
Polyamines | 2 | 2008 | 133 | 0.360 |
Why?
|
Opiate Substitution Treatment | 3 | 2024 | 436 | 0.350 |
Why?
|
Pain, Postoperative | 5 | 2018 | 1721 | 0.350 |
Why?
|
Gestational Age | 6 | 2024 | 3565 | 0.340 |
Why?
|
Central Nervous System | 1 | 2017 | 1334 | 0.330 |
Why?
|
Risperidone | 3 | 2018 | 379 | 0.330 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3164 | 0.330 |
Why?
|
Aged | 45 | 2024 | 169152 | 0.330 |
Why?
|
Fertility | 3 | 2020 | 773 | 0.330 |
Why?
|
Economics, Pharmaceutical | 2 | 2009 | 88 | 0.330 |
Why?
|
Hypoglycemia | 1 | 2016 | 888 | 0.320 |
Why?
|
Industry | 1 | 2011 | 361 | 0.320 |
Why?
|
Cause of Death | 2 | 2017 | 3725 | 0.320 |
Why?
|
Pyrimidines | 1 | 2021 | 3016 | 0.320 |
Why?
|
Calcinosis | 3 | 2008 | 1476 | 0.310 |
Why?
|
Calcium Carbonate | 1 | 2008 | 62 | 0.310 |
Why?
|
Hyperphosphatemia | 1 | 2008 | 39 | 0.310 |
Why?
|
Algorithms | 9 | 2024 | 13981 | 0.310 |
Why?
|
Cesarean Section | 4 | 2024 | 1385 | 0.310 |
Why?
|
Outpatients | 4 | 2023 | 1607 | 0.300 |
Why?
|
Fetal Growth Retardation | 3 | 2022 | 579 | 0.290 |
Why?
|
Hospital Mortality | 2 | 2018 | 5425 | 0.280 |
Why?
|
Chelating Agents | 1 | 2008 | 384 | 0.280 |
Why?
|
Pregnant Women | 3 | 2021 | 563 | 0.270 |
Why?
|
Lithium Compounds | 2 | 2019 | 225 | 0.270 |
Why?
|
Aged, 80 and over | 18 | 2022 | 58995 | 0.270 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 670 | 0.270 |
Why?
|
Case-Control Studies | 7 | 2021 | 22053 | 0.270 |
Why?
|
Research Personnel | 1 | 2011 | 582 | 0.270 |
Why?
|
Logistic Models | 9 | 2018 | 13314 | 0.270 |
Why?
|
Pregnancy in Diabetics | 2 | 2024 | 194 | 0.260 |
Why?
|
Phosphorus Metabolism Disorders | 1 | 2005 | 9 | 0.260 |
Why?
|
Renal Dialysis | 2 | 2005 | 1801 | 0.260 |
Why?
|
Hemorrhage | 4 | 2020 | 3600 | 0.260 |
Why?
|
Pregnancy Trimesters | 2 | 2017 | 197 | 0.250 |
Why?
|
Infant | 12 | 2024 | 36060 | 0.250 |
Why?
|
Mental Disorders | 3 | 2021 | 6796 | 0.250 |
Why?
|
Epoxy Compounds | 1 | 2005 | 137 | 0.250 |
Why?
|
Patient Compliance | 4 | 2020 | 2688 | 0.240 |
Why?
|
United States Food and Drug Administration | 5 | 2024 | 1677 | 0.240 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5325 | 0.240 |
Why?
|
Hypertension | 8 | 2024 | 8594 | 0.240 |
Why?
|
Fathers | 2 | 2024 | 376 | 0.240 |
Why?
|
Teratogens | 2 | 2023 | 117 | 0.240 |
Why?
|
Pyridones | 2 | 2020 | 792 | 0.240 |
Why?
|
Phenylpropionates | 1 | 2024 | 35 | 0.230 |
Why?
|
Epidemiologic Methods | 4 | 2013 | 1343 | 0.230 |
Why?
|
Proportional Hazards Models | 7 | 2022 | 12531 | 0.230 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39261 | 0.230 |
Why?
|
Prescriptions | 4 | 2022 | 388 | 0.230 |
Why?
|
Dextroamphetamine | 1 | 2024 | 134 | 0.220 |
Why?
|
Hepatitis C, Chronic | 2 | 2022 | 1031 | 0.220 |
Why?
|
Chlorprothixene | 1 | 2023 | 3 | 0.220 |
Why?
|
Residence Characteristics | 2 | 2013 | 2062 | 0.220 |
Why?
|
Pain | 5 | 2022 | 5066 | 0.210 |
Why?
|
Polyethylenes | 1 | 2005 | 290 | 0.210 |
Why?
|
Pregnancy Trimester, Second | 2 | 2024 | 732 | 0.210 |
Why?
|
Birth Certificates | 1 | 2022 | 70 | 0.210 |
Why?
|
Placenta | 2 | 2022 | 1702 | 0.210 |
Why?
|
Liver Function Tests | 1 | 2024 | 524 | 0.210 |
Why?
|
Infant, Low Birth Weight | 2 | 2024 | 859 | 0.210 |
Why?
|
Pyridazines | 1 | 2024 | 200 | 0.210 |
Why?
|
Delivery, Obstetric | 4 | 2020 | 932 | 0.200 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1824 | 0.200 |
Why?
|
Cardiotonic Agents | 1 | 2005 | 546 | 0.200 |
Why?
|
Models, Statistical | 5 | 2021 | 5075 | 0.200 |
Why?
|
Statistics as Topic | 3 | 2018 | 2362 | 0.200 |
Why?
|
Models, Economic | 3 | 2008 | 719 | 0.200 |
Why?
|
Hypertension, Pregnancy-Induced | 3 | 2024 | 518 | 0.200 |
Why?
|
Time Factors | 10 | 2022 | 40165 | 0.190 |
Why?
|
Tetanus | 1 | 2021 | 51 | 0.190 |
Why?
|
Meta-Analysis as Topic | 1 | 2006 | 1376 | 0.190 |
Why?
|
Diphtheria | 1 | 2021 | 33 | 0.190 |
Why?
|
Insurance | 1 | 2023 | 114 | 0.190 |
Why?
|
Epilepsy, Generalized | 1 | 2023 | 178 | 0.190 |
Why?
|
Budgets | 2 | 2017 | 230 | 0.190 |
Why?
|
Calcium Channel Blockers | 2 | 2015 | 694 | 0.190 |
Why?
|
For-Profit Insurance Plans | 1 | 2020 | 8 | 0.190 |
Why?
|
Drug Combinations | 2 | 2024 | 2025 | 0.190 |
Why?
|
Whooping Cough | 1 | 2021 | 85 | 0.180 |
Why?
|
Drug Labeling | 2 | 2024 | 251 | 0.180 |
Why?
|
Ozone | 1 | 2024 | 477 | 0.180 |
Why?
|
Pregnancy Trimester, Third | 4 | 2015 | 582 | 0.180 |
Why?
|
Mycoses | 1 | 2023 | 387 | 0.180 |
Why?
|
Managed Care Programs | 1 | 2005 | 939 | 0.170 |
Why?
|
Analgesia, Obstetrical | 1 | 2021 | 169 | 0.170 |
Why?
|
Myocardial Infarction | 3 | 2018 | 11891 | 0.170 |
Why?
|
Hydrocodone | 2 | 2022 | 48 | 0.170 |
Why?
|
Labetalol | 2 | 2016 | 29 | 0.170 |
Why?
|
Codeine | 2 | 2022 | 51 | 0.170 |
Why?
|
Child, Hospitalized | 1 | 2021 | 182 | 0.170 |
Why?
|
Contraceptive Agents, Female | 1 | 2020 | 118 | 0.170 |
Why?
|
Pyrazoles | 2 | 2020 | 1999 | 0.170 |
Why?
|
Birth Rate | 1 | 2020 | 168 | 0.170 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 334 | 0.170 |
Why?
|
Dibenzothiazepines | 2 | 2012 | 102 | 0.160 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2020 | 100 | 0.160 |
Why?
|
Hepatitis C | 2 | 2022 | 1579 | 0.160 |
Why?
|
Kidney Failure, Chronic | 3 | 2008 | 2471 | 0.160 |
Why?
|
Data Interpretation, Statistical | 3 | 2020 | 2696 | 0.160 |
Why?
|
Insulin | 5 | 2024 | 6597 | 0.160 |
Why?
|
Confidence Intervals | 2 | 2015 | 2932 | 0.160 |
Why?
|
Osteoporosis | 2 | 2005 | 1600 | 0.160 |
Why?
|
Retrospective Studies | 14 | 2023 | 80372 | 0.160 |
Why?
|
Cardiovascular Abnormalities | 1 | 2019 | 143 | 0.160 |
Why?
|
European Union | 1 | 2019 | 157 | 0.160 |
Why?
|
Thalidomide | 1 | 2024 | 884 | 0.160 |
Why?
|
Drug Interactions | 2 | 2020 | 1428 | 0.160 |
Why?
|
DiGeorge Syndrome | 1 | 2020 | 185 | 0.160 |
Why?
|
Prospective Studies | 11 | 2023 | 54303 | 0.150 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2021 | 618 | 0.150 |
Why?
|
Health Planning | 1 | 2019 | 232 | 0.150 |
Why?
|
Analgesics | 3 | 2024 | 1065 | 0.150 |
Why?
|
Isotretinoin | 1 | 2019 | 131 | 0.150 |
Why?
|
Veterans | 2 | 2022 | 2642 | 0.150 |
Why?
|
Epilepsy | 3 | 2024 | 3267 | 0.150 |
Why?
|
Abortion, Induced | 1 | 2023 | 460 | 0.150 |
Why?
|
Epidemiologic Research Design | 1 | 2021 | 368 | 0.150 |
Why?
|
Internet | 1 | 2010 | 3078 | 0.150 |
Why?
|
Perinatal Care | 1 | 2020 | 242 | 0.150 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1385 | 0.150 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2022 | 622 | 0.150 |
Why?
|
Medical Records | 1 | 2023 | 1407 | 0.140 |
Why?
|
Maternal Age | 2 | 2023 | 807 | 0.140 |
Why?
|
Infertility, Male | 1 | 2020 | 396 | 0.140 |
Why?
|
Registries | 5 | 2018 | 8469 | 0.140 |
Why?
|
Computer Simulation | 4 | 2020 | 6218 | 0.140 |
Why?
|
Oocyte Retrieval | 1 | 2018 | 158 | 0.140 |
Why?
|
Treatment Failure | 1 | 2023 | 2648 | 0.140 |
Why?
|
Drug Utilization Review | 1 | 2018 | 251 | 0.140 |
Why?
|
Probability | 2 | 2019 | 2475 | 0.140 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3388 | 0.140 |
Why?
|
Microcephaly | 1 | 2020 | 425 | 0.140 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2017 | 186 | 0.140 |
Why?
|
Gastrointestinal Agents | 1 | 2021 | 509 | 0.140 |
Why?
|
Vascular Diseases | 1 | 2005 | 1182 | 0.130 |
Why?
|
Drug Substitution | 1 | 2019 | 296 | 0.130 |
Why?
|
Tretinoin | 1 | 2019 | 519 | 0.130 |
Why?
|
Atenolol | 1 | 2016 | 99 | 0.130 |
Why?
|
Incidence | 6 | 2021 | 21392 | 0.130 |
Why?
|
Metoprolol | 1 | 2016 | 92 | 0.130 |
Why?
|
Office Visits | 1 | 2020 | 597 | 0.130 |
Why?
|
Predictive Value of Tests | 3 | 2023 | 15289 | 0.130 |
Why?
|
Medication Adherence | 2 | 2020 | 2165 | 0.130 |
Why?
|
Particulate Matter | 2 | 2024 | 2559 | 0.130 |
Why?
|
Morphine | 2 | 2022 | 655 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15840 | 0.130 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 209 | 0.130 |
Why?
|
Odds Ratio | 5 | 2018 | 9716 | 0.130 |
Why?
|
Vaccination | 3 | 2023 | 3361 | 0.130 |
Why?
|
Puerperal Disorders | 1 | 2018 | 300 | 0.130 |
Why?
|
Zidovudine | 1 | 2017 | 624 | 0.130 |
Why?
|
Pandemics | 4 | 2023 | 8624 | 0.130 |
Why?
|
Advisory Committees | 1 | 2019 | 788 | 0.120 |
Why?
|
Antidepressive Agents, Tricyclic | 2 | 2014 | 432 | 0.120 |
Why?
|
Cost of Illness | 4 | 2003 | 1940 | 0.120 |
Why?
|
Drug Packaging | 1 | 2014 | 43 | 0.120 |
Why?
|
Patient Simulation | 1 | 2017 | 297 | 0.120 |
Why?
|
Spondylitis, Ankylosing | 1 | 2016 | 152 | 0.120 |
Why?
|
Anxiety | 2 | 2022 | 4538 | 0.120 |
Why?
|
Incidental Findings | 1 | 2019 | 698 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2022 | 10827 | 0.120 |
Why?
|
Data Collection | 3 | 2014 | 3315 | 0.120 |
Why?
|
Autistic Disorder | 1 | 2024 | 1216 | 0.120 |
Why?
|
Lithium | 1 | 2017 | 596 | 0.120 |
Why?
|
Papillomavirus Vaccines | 1 | 2020 | 495 | 0.120 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.120 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 831 | 0.120 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 4878 | 0.110 |
Why?
|
Intraoperative Care | 1 | 2018 | 768 | 0.110 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2022 | 4555 | 0.110 |
Why?
|
Methylergonovine | 1 | 2013 | 6 | 0.110 |
Why?
|
Paternal Exposure | 2 | 2024 | 94 | 0.110 |
Why?
|
Reproduction | 1 | 2018 | 646 | 0.110 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4491 | 0.110 |
Why?
|
Denmark | 2 | 2020 | 760 | 0.110 |
Why?
|
Hospitals, Community | 1 | 2016 | 367 | 0.110 |
Why?
|
Clozapine | 1 | 2017 | 506 | 0.110 |
Why?
|
Cardiomyopathies | 1 | 2005 | 1952 | 0.110 |
Why?
|
Air Pollution | 2 | 2024 | 2317 | 0.110 |
Why?
|
Postoperative Period | 1 | 2018 | 1818 | 0.110 |
Why?
|
Arthritis, Psoriatic | 1 | 2016 | 219 | 0.110 |
Why?
|
Air Pollutants | 2 | 2024 | 2844 | 0.110 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 25942 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1830 | 0.100 |
Why?
|
Treatment Outcome | 10 | 2022 | 65017 | 0.100 |
Why?
|
Thrombophilia | 1 | 2015 | 306 | 0.100 |
Why?
|
HIV Infections | 4 | 2021 | 17165 | 0.100 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2015 | 345 | 0.100 |
Why?
|
Cardiac Surgical Procedures | 2 | 2018 | 3620 | 0.100 |
Why?
|
Medicare | 4 | 2020 | 6786 | 0.100 |
Why?
|
Multivariate Analysis | 6 | 2016 | 12159 | 0.100 |
Why?
|
Propylamines | 1 | 2012 | 161 | 0.100 |
Why?
|
Primary Health Care | 2 | 2019 | 4647 | 0.100 |
Why?
|
Government Regulation | 1 | 2016 | 525 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 3201 | 0.100 |
Why?
|
Ambulatory Care | 3 | 2018 | 2781 | 0.100 |
Why?
|
Analgesia | 1 | 2016 | 459 | 0.100 |
Why?
|
Medical Assistance | 1 | 2012 | 107 | 0.100 |
Why?
|
Delirium | 3 | 2018 | 1663 | 0.090 |
Why?
|
Reminder Systems | 1 | 2014 | 387 | 0.090 |
Why?
|
Sulfonylurea Compounds | 2 | 2024 | 221 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1869 | 0.090 |
Why?
|
British Columbia | 1 | 2011 | 240 | 0.090 |
Why?
|
Achievement | 1 | 2012 | 289 | 0.090 |
Why?
|
Child, Preschool | 3 | 2023 | 42063 | 0.090 |
Why?
|
Thiazoles | 1 | 2018 | 1511 | 0.090 |
Why?
|
Anesthesia, General | 1 | 2018 | 1166 | 0.090 |
Why?
|
Asthma | 2 | 2020 | 6172 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2282 | 0.090 |
Why?
|
Publication Bias | 1 | 2011 | 162 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3696 | 0.090 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 700 | 0.090 |
Why?
|
Linear Models | 3 | 2017 | 5877 | 0.090 |
Why?
|
Fetal Diseases | 1 | 2015 | 911 | 0.090 |
Why?
|
beta-Thalassemia | 2 | 2002 | 235 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2016 | 1328 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2021 | 1919 | 0.080 |
Why?
|
Chronic Disease | 3 | 2024 | 9287 | 0.080 |
Why?
|
Crohn Disease | 1 | 2021 | 2275 | 0.080 |
Why?
|
Mental Health | 1 | 2023 | 3213 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2020 | 1607 | 0.080 |
Why?
|
Income | 1 | 2017 | 1875 | 0.080 |
Why?
|
Patient Discharge | 2 | 2018 | 3476 | 0.080 |
Why?
|
Inpatients | 3 | 2016 | 2581 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3465 | 0.080 |
Why?
|
Prognosis | 5 | 2019 | 29658 | 0.080 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4166 | 0.080 |
Why?
|
Perioperative Care | 1 | 2016 | 1037 | 0.080 |
Why?
|
Cross-Over Studies | 2 | 2024 | 2061 | 0.080 |
Why?
|
Acetaminophen | 2 | 2023 | 553 | 0.080 |
Why?
|
Life Style | 1 | 2019 | 3896 | 0.080 |
Why?
|
Greece | 1 | 2008 | 336 | 0.070 |
Why?
|
Menstrual Cycle | 1 | 2011 | 536 | 0.070 |
Why?
|
Sweden | 2 | 2021 | 1381 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14660 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3905 | 0.070 |
Why?
|
Smoking | 3 | 2019 | 9073 | 0.070 |
Why?
|
Femoral Fractures | 1 | 2011 | 375 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2008 | 15757 | 0.070 |
Why?
|
Canada | 3 | 2008 | 2128 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1588 | 0.070 |
Why?
|
Biological Products | 1 | 2016 | 916 | 0.070 |
Why?
|
Respiration, Artificial | 1 | 2018 | 2622 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14495 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6544 | 0.070 |
Why?
|
Calcium Compounds | 1 | 2005 | 38 | 0.060 |
Why?
|
Direct Service Costs | 1 | 2005 | 60 | 0.060 |
Why?
|
Regression Analysis | 2 | 2005 | 6360 | 0.060 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2016 | 1406 | 0.060 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2016 | 1370 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1931 | 0.060 |
Why?
|
Health Care Costs | 3 | 2006 | 3258 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2021 | 4775 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2093 | 0.060 |
Why?
|
Deferoxamine | 2 | 2002 | 153 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2250 | 0.060 |
Why?
|
Antimanic Agents | 2 | 2019 | 520 | 0.060 |
Why?
|
Embolism | 2 | 2020 | 408 | 0.060 |
Why?
|
Acetates | 1 | 2005 | 321 | 0.060 |
Why?
|
Time | 1 | 2005 | 545 | 0.060 |
Why?
|
Poverty | 1 | 2015 | 2695 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2011 | 21025 | 0.060 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2159 | 0.050 |
Why?
|
Fertilization | 1 | 2024 | 197 | 0.050 |
Why?
|
Spermatogenesis | 1 | 2024 | 257 | 0.050 |
Why?
|
Length of Stay | 5 | 2017 | 6479 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2011 | 2326 | 0.050 |
Why?
|
Mifepristone | 1 | 2023 | 150 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Fractures, Bone | 2 | 2005 | 2041 | 0.050 |
Why?
|
Substance-Related Disorders | 2 | 2016 | 4371 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Seizures | 1 | 2015 | 2917 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10344 | 0.050 |
Why?
|
Recurrence | 3 | 2018 | 8482 | 0.050 |
Why?
|
Pravastatin | 2 | 2003 | 393 | 0.050 |
Why?
|
Socioeconomic Factors | 3 | 2024 | 7806 | 0.050 |
Why?
|
Hydromorphone | 1 | 2022 | 70 | 0.050 |
Why?
|
Postpartum Period | 2 | 2023 | 1167 | 0.050 |
Why?
|
Anxiety Disorders | 1 | 2013 | 2714 | 0.050 |
Why?
|
Aminosalicylic Acid | 1 | 2021 | 20 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2283 | 0.050 |
Why?
|
Israel | 1 | 2024 | 722 | 0.050 |
Why?
|
Phosphates | 1 | 2005 | 772 | 0.050 |
Why?
|
Age Factors | 6 | 2020 | 18416 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2005 | 1724 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9467 | 0.050 |
Why?
|
Sulfasalazine | 1 | 2021 | 84 | 0.050 |
Why?
|
Iron Chelating Agents | 1 | 2002 | 138 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2012 | 7475 | 0.050 |
Why?
|
Disability Evaluation | 1 | 2008 | 1826 | 0.050 |
Why?
|
Oxycodone | 1 | 2022 | 138 | 0.050 |
Why?
|
Nitrogen Dioxide | 1 | 2024 | 512 | 0.050 |
Why?
|
Monte Carlo Method | 3 | 2015 | 1257 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2016 | 3763 | 0.040 |
Why?
|
New South Wales | 1 | 2020 | 70 | 0.040 |
Why?
|
Sex Factors | 4 | 2020 | 10547 | 0.040 |
Why?
|
Naproxen | 1 | 2020 | 100 | 0.040 |
Why?
|
Sertraline | 1 | 2021 | 208 | 0.040 |
Why?
|
Sexual Behavior | 1 | 2010 | 2086 | 0.040 |
Why?
|
Schizophrenia | 1 | 2019 | 6915 | 0.040 |
Why?
|
Hong Kong | 1 | 2020 | 162 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2003 | 435 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2013 | 2365 | 0.040 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2024 | 497 | 0.040 |
Why?
|
Australia | 2 | 2020 | 1289 | 0.040 |
Why?
|
Family Relations | 1 | 2002 | 318 | 0.040 |
Why?
|
Obesity | 2 | 2019 | 12922 | 0.040 |
Why?
|
Continuity of Patient Care | 1 | 2006 | 1066 | 0.040 |
Why?
|
Environmental Exposure | 2 | 2024 | 4412 | 0.040 |
Why?
|
Ibuprofen | 1 | 2020 | 229 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2010 | 5201 | 0.040 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 136 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 244 | 0.040 |
Why?
|
Finland | 1 | 2020 | 603 | 0.040 |
Why?
|
Norway | 1 | 2020 | 496 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2014 | 4360 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2003 | 570 | 0.040 |
Why?
|
Temperature | 1 | 2024 | 2221 | 0.040 |
Why?
|
Germany | 1 | 2020 | 873 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20080 | 0.040 |
Why?
|
Patient Selection | 1 | 2010 | 4283 | 0.040 |
Why?
|
Spain | 1 | 2019 | 488 | 0.040 |
Why?
|
Long-Term Care | 1 | 2002 | 632 | 0.040 |
Why?
|
Blood Glucose | 2 | 2023 | 6381 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 145 | 0.040 |
Why?
|
Age Distribution | 1 | 2023 | 2893 | 0.040 |
Why?
|
Italy | 1 | 2019 | 841 | 0.030 |
Why?
|
Anticholesteremic Agents | 2 | 2003 | 987 | 0.030 |
Why?
|
Quality Improvement | 1 | 2012 | 3836 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 595 | 0.030 |
Why?
|
Pregnancy Rate | 1 | 2019 | 649 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2020 | 755 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15697 | 0.030 |
Why?
|
Policy Making | 1 | 2019 | 538 | 0.030 |
Why?
|
Tidal Volume | 1 | 2018 | 487 | 0.030 |
Why?
|
Survival Analysis | 1 | 2008 | 10182 | 0.030 |
Why?
|
Health Services | 1 | 2020 | 753 | 0.030 |
Why?
|
Triazines | 1 | 2017 | 310 | 0.030 |
Why?
|
Hepacivirus | 1 | 2022 | 1334 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2002 | 2435 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2016 | 450 | 0.030 |
Why?
|
Anti-Asthmatic Agents | 1 | 2019 | 565 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2015 | 641 | 0.030 |
Why?
|
Brain Ischemia | 2 | 2015 | 3127 | 0.030 |
Why?
|
Methyldopa | 1 | 2013 | 18 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1999 | 1677 | 0.030 |
Why?
|
Primary Prevention | 2 | 2018 | 1207 | 0.030 |
Why?
|
Insurance Coverage | 2 | 2015 | 1939 | 0.030 |
Why?
|
Positive-Pressure Respiration | 1 | 2018 | 636 | 0.030 |
Why?
|
Policy | 1 | 2017 | 511 | 0.030 |
Why?
|
Obstetrics | 1 | 2020 | 667 | 0.030 |
Why?
|
Hospital Costs | 1 | 1999 | 976 | 0.030 |
Why?
|
Heart Rate | 1 | 2005 | 4179 | 0.030 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1570 | 0.030 |
Why?
|
Electrocardiography | 1 | 2006 | 6414 | 0.030 |
Why?
|
Electronics | 1 | 2014 | 315 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1579 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2013 | 187 | 0.030 |
Why?
|
Language Arts | 1 | 2012 | 2 | 0.030 |
Why?
|
Polypharmacy | 1 | 2015 | 307 | 0.030 |
Why?
|
Infertility, Female | 1 | 2018 | 759 | 0.030 |
Why?
|
Iceland | 1 | 2012 | 184 | 0.030 |
Why?
|
Back Pain | 1 | 2016 | 543 | 0.020 |
Why?
|
Family | 1 | 2023 | 3189 | 0.020 |
Why?
|
Maternal Health Services | 1 | 2017 | 455 | 0.020 |
Why?
|
Ultrasonography | 1 | 2005 | 5961 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1004 | 0.020 |
Why?
|
Infant, Premature | 1 | 2021 | 2092 | 0.020 |
Why?
|
Ultrasonography, Prenatal | 1 | 2019 | 1745 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2018 | 1548 | 0.020 |
Why?
|
Thromboembolism | 1 | 2018 | 1017 | 0.020 |
Why?
|
Mathematics | 1 | 2012 | 707 | 0.020 |
Why?
|
Quality of Life | 3 | 2009 | 13308 | 0.020 |
Why?
|
Health Expenditures | 1 | 2003 | 2362 | 0.020 |
Why?
|
Mothers | 1 | 2021 | 2186 | 0.020 |
Why?
|
Forecasting | 1 | 1999 | 2932 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2017 | 2659 | 0.020 |
Why?
|
Glucose | 1 | 2021 | 4351 | 0.020 |
Why?
|
Blood Pressure | 1 | 2005 | 8525 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8056 | 0.020 |
Why?
|
Aspirin | 1 | 2020 | 3364 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 12960 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8803 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9280 | 0.020 |
Why?
|
Medical Informatics | 1 | 2014 | 732 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2024 | 5130 | 0.020 |
Why?
|
Coronary Disease | 1 | 2000 | 5990 | 0.020 |
Why?
|
Educational Measurement | 1 | 2012 | 1248 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2015 | 1200 | 0.020 |
Why?
|
Saskatchewan | 1 | 2004 | 9 | 0.020 |
Why?
|
Software | 1 | 2018 | 4419 | 0.010 |
Why?
|
Cerebral Hemorrhage | 1 | 2015 | 2660 | 0.010 |
Why?
|
Migraine Disorders | 1 | 2016 | 1693 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13502 | 0.010 |
Why?
|
Chelation Therapy | 1 | 2002 | 77 | 0.010 |
Why?
|
Belgium | 1 | 2000 | 118 | 0.010 |
Why?
|
Scotland | 1 | 2000 | 143 | 0.010 |
Why?
|
Iron Overload | 1 | 2002 | 240 | 0.010 |
Why?
|
Sepsis | 1 | 2013 | 2592 | 0.010 |
Why?
|
Endocrine System Diseases | 1 | 2002 | 250 | 0.010 |
Why?
|
Thyroid Diseases | 1 | 2002 | 386 | 0.010 |
Why?
|
Drug Costs | 1 | 2006 | 1185 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2003 | 968 | 0.010 |
Why?
|
Cost Savings | 1 | 2003 | 920 | 0.010 |
Why?
|
National Health Programs | 1 | 2001 | 441 | 0.010 |
Why?
|
Demography | 1 | 2001 | 1650 | 0.010 |
Why?
|
Health Services Research | 1 | 2003 | 1810 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2002 | 1341 | 0.010 |
Why?
|
Europe | 1 | 2001 | 3441 | 0.010 |
Why?
|
International Cooperation | 1 | 2000 | 1433 | 0.010 |
Why?
|
Liver Diseases | 1 | 2002 | 1302 | 0.010 |
Why?
|
Health Policy | 1 | 2003 | 2677 | 0.010 |
Why?
|
Disease Management | 1 | 2001 | 2514 | 0.010 |
Why?
|
Heart Failure | 1 | 2013 | 11847 | 0.010 |
Why?
|
Heart Diseases | 1 | 2002 | 2809 | 0.000 |
Why?
|
Health Status | 1 | 2001 | 4081 | 0.000 |
Why?
|
Referral and Consultation | 1 | 2000 | 3598 | 0.000 |
Why?
|
Survival Rate | 1 | 2001 | 12808 | 0.000 |
Why?
|